Poland · Delayed Price · Currency is PLN Celon Pharma Statistics
Total Valuation
Celon Pharma has a market cap or net worth of PLN 1.11 billion. The enterprise value is 1.16 billion.
| Market Cap | 1.11B |
| Enterprise Value | 1.16B |
Important Dates
The next confirmed earnings date is Wednesday, September 16, 2026.
| Earnings Date | Sep 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Celon Pharma has 53.86 million shares outstanding. The number of shares has decreased by -2.29% in one year.
| Current Share Class | 38.86M |
| Shares Outstanding | 53.86M |
| Shares Change (YoY) | -2.29% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 17.98% |
| Float | 23.82M |
Valuation Ratios
The trailing PE ratio is 10.13 and the forward PE ratio is 337.01.
| PE Ratio | 10.13 |
| Forward PE | 337.01 |
| PS Ratio | 4.37 |
| PB Ratio | 2.10 |
| P/TBV Ratio | 2.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 36.50 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 10.68 |
| EV / Sales | 4.55 |
| EV / EBITDA | 54.01 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.20, with a Debt / Equity ratio of 0.10.
| Current Ratio | 1.20 |
| Quick Ratio | 0.87 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 2.51 |
| Debt / FCF | -1.55 |
| Interest Coverage | -15.51 |
Financial Efficiency
Return on equity (ROE) is 22.84% and return on invested capital (ROIC) is -2.27%.
| Return on Equity (ROE) | 22.84% |
| Return on Assets (ROA) | -1.27% |
| Return on Invested Capital (ROIC) | -2.27% |
| Return on Capital Employed (ROCE) | -4.26% |
| Weighted Average Cost of Capital (WACC) | 7.68% |
| Revenue Per Employee | 451,087 |
| Profits Per Employee | 192,055 |
| Employee Count | 564 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.35 |
Taxes
In the past 12 months, Celon Pharma has paid 15.56 million in taxes.
| Income Tax | 15.56M |
| Effective Tax Rate | 12.56% |
Stock Price Statistics
The stock price has decreased by -14.32% in the last 52 weeks. The beta is 0.67, so Celon Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -14.32% |
| 50-Day Moving Average | 20.41 |
| 200-Day Moving Average | 21.12 |
| Relative Strength Index (RSI) | 55.85 |
| Average Volume (20 Days) | 8,076 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celon Pharma had revenue of PLN 254.41 million and earned 108.32 million in profits. Earnings per share was 2.04.
| Revenue | 254.41M |
| Gross Profit | 189.07M |
| Operating Income | -12.13M |
| Pretax Income | 123.88M |
| Net Income | 108.32M |
| EBITDA | 21.42M |
| EBIT | -24.87M |
| Earnings Per Share (EPS) | 2.04 |
Balance Sheet
The company has 9.09 million in cash and 53.68 million in debt, with a net cash position of -44.58 million or -0.83 per share.
| Cash & Cash Equivalents | 9.09M |
| Total Debt | 53.68M |
| Net Cash | -44.58M |
| Net Cash Per Share | -0.83 |
| Equity (Book Value) | 528.78M |
| Book Value Per Share | 9.82 |
| Working Capital | 17.85M |
Cash Flow
In the last 12 months, operating cash flow was 30.47 million and capital expenditures -65.08 million, giving a free cash flow of -34.61 million.
| Operating Cash Flow | 30.47M |
| Capital Expenditures | -65.08M |
| Depreciation & Amortization | 31.28M |
| Net Borrowing | -847,000 |
| Free Cash Flow | -34.61M |
| FCF Per Share | -0.64 |
Margins
Gross margin is 74.32%, with operating and profit margins of -4.77% and 42.58%.
| Gross Margin | 74.32% |
| Operating Margin | -4.77% |
| Pretax Margin | 48.69% |
| Profit Margin | 42.58% |
| EBITDA Margin | 7.53% |
| EBIT Margin | -4.77% |
| FCF Margin | n/a |
Dividends & Yields
Celon Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.29% |
| Shareholder Yield | 2.29% |
| Earnings Yield | 9.74% |
| FCF Yield | -3.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Celon Pharma is 20.44, which is -1.02% lower than the current price. The consensus rating is "Hold".
| Price Target | 20.44 |
| Price Target Difference | -1.02% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 9.39% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Celon Pharma has an Altman Z-Score of 5.44 and a Piotroski F-Score of 4.
| Altman Z-Score | 5.44 |
| Piotroski F-Score | 4 |